Giredestrant (GDC-9545, RG6171)

A novel, oral, selective estrogen receptor degrader (SERD)

Giredestrant is an investigational molecule designed to inhibit the ER¹

ER=estrogen receptor.

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

© 2023 Genentech USA, Inc. All rights reserved. M-US-00019864(v1.0)